{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T10:01:33Z","timestamp":1790848893565,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":86,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Institutes for Allergy and Infectious Diseases at the National Institutes of Health","award":["UM1AI104681"],"award-info":[{"award-number":["UM1AI104681"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-13946-8","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T15:24:53Z","timestamp":1783437893000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Distinct molecular epidemiology and outcomes of carbapenem-resistant gram-negative infections in Lebanon: insights from the MDRO network"],"prefix":"10.1186","volume":"26","author":[{"given":"Jean-Francois","family":"Jabbour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hind","family":"Kadri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elio","family":"Jabra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joya-Rita","family":"Hindy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara F.","family":"Haddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeina A.","family":"Kanafani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada K.","family":"Zahreddine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine G.","family":"Abou Fayad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Komarow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George F.","family":"Araj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghassan M.","family":"Matar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Doi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Vance G.","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Paterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Satlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"van Duin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souha S.","family":"Kanj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"13946_CR1","unstructured":"World Health Organization. WHO bacterial priority pathogens list. 2024: Bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance. Geneva: World Health Organization; 2024. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240093461"},{"key":"13946_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.jgar.2021.02.033","volume":"25","author":"A Sleiman","year":"2021","unstructured":"Sleiman A, Fayad AGA, Banna H, Matar GM. Prevalence and molecular epidemiology of carbapenem-resistant Gram-negative bacilli and their resistance determinants in the Eastern Mediterranean Region over the last decade. J Glob Antimicrob Resist. 2021;25:209\u201321. https:\/\/doi.org\/10.1016\/j.jgar.2021.02.033.","journal-title":"J Glob Antimicrob Resist"},{"issue":"11","key":"13946_CR3","doi-asserted-by":"publisher","first-page":"e1002184","DOI":"10.1371\/journal.pmed.1002184","volume":"13","author":"MEA de Kraker","year":"2016","unstructured":"de Kraker MEA, Stewardson AJ, Harbarth S. Will 10 million people die a year due to antimicrobial resistance by 2050? PLoS Med. 2016;13(11):e1002184. https:\/\/doi.org\/10.1371\/journal.pmed.1002184.","journal-title":"PLoS Med"},{"issue":"11","key":"13946_CR4","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.3390\/antibiotics10111320","volume":"10","author":"NA Rizk","year":"2021","unstructured":"Rizk NA, Moghnieh R, Haddad N, Rebeiz MC, Zeenny RM, Hindy JR, et al. Challenges to antimicrobial stewardship in the countries of the Arab League: concerns of worsening resistance during the COVID-19 Pandemic and proposed solutions. Antibiot (Basel). 2021;10(11):1320. https:\/\/doi.org\/10.3390\/antibiotics10111320.","journal-title":"Antibiot (Basel)"},{"issue":"3","key":"13946_CR5","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.jiph.2022.12.022","volume":"16","author":"U Abubakar","year":"2023","unstructured":"Abubakar U, Al-Anazi M, Alanazi Z, Rodr\u00edguez-Ba\u00f1o J. Impact of COVID-19 pandemic on multidrug resistant Gram-positive and Gram-negative pathogens: A systematic review. J Infect Public Health. 2023;16(3):320\u201331. https:\/\/doi.org\/10.1016\/j.jiph.2022.12.022.","journal-title":"J Infect Public Health"},{"key":"13946_CR6","volume-title":"Report of the 6th meeting of the WHO advisory group on integrated surveillance of antimicrobial resistance with AGISAR 5-year strategic framework to support implementation of the global action plan on antimicrobial resistance (2015\u20132019)","author":"World Health Organization","year":"2015","unstructured":"World Health Organization. Report of the 6th meeting of the WHO advisory group on integrated surveillance of antimicrobial resistance with AGISAR 5-year strategic framework to support implementation of the global action plan on antimicrobial resistance (2015\u20132019). Seoul: World Health Organization; 2015."},{"issue":"7","key":"13946_CR7","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.jiph.2021.04.009","volume":"14","author":"J Al Salman","year":"2021","unstructured":"Al Salman J, Al Dabal L, Bassetti M, Alfouzan WA, Al Maslamani M, Alraddadi B, et al. Promoting cross-regional collaboration in antimicrobial stewardship: findings of an infectious diseases working group survey in Arab countries of the Middle East. J Infect Public Health. 2021;14(7):978\u201384. https:\/\/doi.org\/10.1016\/j.jiph.2021.04.009.","journal-title":"J Infect Public Health"},{"issue":"12","key":"13946_CR8","doi-asserted-by":"publisher","first-page":"e379","DOI":"10.1016\/S1473-3099(18)30414-6","volume":"18","author":"RA Moghnieh","year":"2018","unstructured":"Moghnieh RA, Kanafani ZA, Tabaja HZ, Sharara SL, Awad LS, Kanj SS. Epidemiology of common resistant bacterial pathogens in the countries of the Arab League. Lancet Infect Dis. 2018;18(12):e379\u201394. https:\/\/doi.org\/10.1016\/S1473-3099(18)30414-6.","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"13946_CR9","doi-asserted-by":"publisher","first-page":"e00105","DOI":"10.1128\/mSphere.00202-21","volume":"6","author":"M Al-Orphaly","year":"2021","unstructured":"Al-Orphaly M, Hadi HA, Eltayeb FK, Al-Hail H, Samuel BG, Sultan AA, et al. Epidemiology of multidrug-resistant Pseudomonas aeruginosa in the Middle East and North Africa Region. mSphere. 2021;6(3):e00105\u201321. https:\/\/doi.org\/10.1128\/mSphere.00202-21.","journal-title":"mSphere"},{"issue":"1","key":"13946_CR10","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1086\/502298","volume":"25","author":"R Fadel","year":"2004","unstructured":"Fadel R, Dakdouki GK, Kanafani ZA, Araj GF, Kanj SS. Clinical and microbiological profile of urinary tract infection at a tertiary-care center in Lebanon. Infect Control Hosp Epidemiol. 2004;25(1):82\u20135. https:\/\/doi.org\/10.1086\/502298.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"2","key":"13946_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3823\/823","volume":"8","author":"M Hamze","year":"2018","unstructured":"Hamze M. Epidemiology and antibiotic susceptibility patterns of carbapenem resistant Gram-negative bacteria isolated from two tertiary care hospitals in North Lebanon. Int Arab J Antimicrob Agents. 2018;8(2):1\u20137. https:\/\/doi.org\/10.3823\/823.","journal-title":"Int Arab J Antimicrob Agents"},{"key":"13946_CR12","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ijid.2016.03.010","volume":"46","author":"K Chamoun","year":"2016","unstructured":"Chamoun K, Farah M, Araj G, Daoud Z, Moghnieh R, Salameh P, et al. Surveillance of antimicrobial resistance in Lebanese hospitals: retrospective nationwide compiled data. Int J Infect Dis. 2016;46:64\u201370. https:\/\/doi.org\/10.1016\/j.ijid.2016.03.010.","journal-title":"Int J Infect Dis"},{"issue":"6","key":"13946_CR13","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/S1473-3099(19)30755-8","volume":"20","author":"D van Duin","year":"2020","unstructured":"van Duin D, Arias CA, Komarow L, Chen L, Hanson B, Weston G, et al. Molecular and clinical epidemiology of carbapenem-resistant Enterobacteriaceae in the United States: a prospective cohort study. Lancet Infect Dis. 2020;20(6):731\u201341. https:\/\/doi.org\/10.1016\/S1473-3099(19)30755-8.","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"13946_CR14","doi-asserted-by":"publisher","first-page":"e159","DOI":"10.1016\/S2666-5247(22)00329-9","volume":"4","author":"J Reyes","year":"2023","unstructured":"Reyes J, Komarow L, Chen L, Ge L, Hanson BM, Cober E, et al. Global epidemiology and clinical outcomes of carbapenem-resistant Pseudomonas aeruginosa and associated carbapenemases (POP): a prospective cohort study. Lancet Microbe. 2023;4(3):e159\u201370. https:\/\/doi.org\/10.1016\/S2666-5247(22)00329-9.","journal-title":"Lancet Microbe"},{"issue":"2","key":"13946_CR15","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1093\/cid\/ciad556","volume":"78","author":"M Wang","year":"2024","unstructured":"Wang M, Ge L, Chen L, Komarow L, Hanson B, Reyes J, et al. Clinical outcomes and bacterial characteristics of carbapenem-resistant Acinetobacter baumannii among patients from different global regions. Clin Infect Dis. 2024;78(2):248\u201358. https:\/\/doi.org\/10.1093\/cid\/ciad556.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"13946_CR16","doi-asserted-by":"publisher","first-page":"4035","DOI":"10.1128\/AAC.02636-14","volume":"58","author":"D van Duin","year":"2014","unstructured":"van Duin D, Perez F, Rudin SD, Cober E, Hanrahan J, Ziegler J, et al. Surveillance of carbapenem-resistant Klebsiella pneumoniae: tracking molecular epidemiology and outcomes through a regional network. Antimicrob Agents Chemother. 2014;58(7):4035\u201341. https:\/\/doi.org\/10.1128\/AAC.02636-14.","journal-title":"Antimicrob Agents Chemother"},{"key":"13946_CR17","unstructured":"Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing, 35th ed. CLSI guideline M100. Wayne (PA): CLSI; 2025."},{"issue":"1","key":"13946_CR18","doi-asserted-by":"publisher","first-page":"e102","DOI":"10.1002\/cpbi.102","volume":"70","author":"A Prjibelski","year":"2020","unstructured":"Prjibelski A, Antipov D, Meleshko D, Lapidus A, Korobeynikov A. Using SPAdes De novo assembler. Curr Protoc Bioinf. 2020;70(1):e102. https:\/\/doi.org\/10.1002\/cpbi.102.","journal-title":"Curr Protoc Bioinf"},{"issue":"1","key":"13946_CR19","doi-asserted-by":"publisher","first-page":"12728","DOI":"10.1038\/s41598-021-91456-0","volume":"11","author":"M Feldgarden","year":"2021","unstructured":"Feldgarden M, Brover V, Gonzalez-Escalona N, Frye JG, Haendiges J, Haft DH, et al. AMRFinderPlus and the reference gene catalog facilitate examination of the genomic links among antimicrobial resistance, stress response, and virulence. Sci Rep. 2021;11(1):12728. https:\/\/doi.org\/10.1038\/s41598-021-91456-0.","journal-title":"Sci Rep"},{"key":"13946_CR20","doi-asserted-by":"publisher","unstructured":"Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America\/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. Clin Infect Dis. 2007;44(Suppl 2). https:\/\/doi.org\/10.1086\/511159. Suppl 2.","DOI":"10.1086\/511159"},{"issue":"4","key":"13946_CR21","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1164\/rccm.200405-644ST","volume":"171","author":"American Thoracic Society, Infectious Diseases Society of America","year":"2005","unstructured":"American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171(4):388\u2013416. https:\/\/doi.org\/10.1164\/rccm.200405-644ST.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"13946_CR22","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ajic.2008.03.002","volume":"36","author":"TC Horan","year":"2008","unstructured":"Horan TC, Andrus M, Dudeck MA. CDC\/NHSN surveillance definition of health care\u2013associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008;36(5):309\u201332. https:\/\/doi.org\/10.1016\/j.ajic.2008.03.002.","journal-title":"Am J Infect Control"},{"issue":"9","key":"13946_CR23","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1093\/cid\/ciz528","volume":"70","author":"H Henderson","year":"2020","unstructured":"Henderson H, Luterbach CL, Cober E, Richter SS, Salata RA, Kalayjian RC, et al. The Pitt Bacteremia Score predicts mortality in nonbacteremic infections. Clin Infect Dis. 2020;70(9):1826\u201333. https:\/\/doi.org\/10.1093\/cid\/ciz528.","journal-title":"Clin Infect Dis"},{"key":"13946_CR24","doi-asserted-by":"publisher","first-page":"6780766","DOI":"10.1155\/cjid\/6780766","volume":"2025","author":"JM Chang","year":"2025","unstructured":"Chang JM, Lin KH, Lai CH, Tsai IT, Hsu YC. The Prognostic Role of Pitt Bacteremia Score in Patients With Nonbacteremic Klebsiella pneumoniae Infections. Can J Infect Dis Med Microbiol. 2025;2025:6780766. https:\/\/doi.org\/10.1155\/cjid\/6780766.","journal-title":"Can J Infect Dis Med Microbiol"},{"issue":"12","key":"13946_CR25","doi-asserted-by":"publisher","first-page":"51","DOI":"10.9734\/ajmah\/2024\/v22i121135","volume":"22","author":"AS Rao","year":"2024","unstructured":"Rao AS, Khan F, Nadeem A, Arsalan. Utility of the PITT Bacteremia Score for Predicting Mortality in CRE Colonized and Infected Patients. Asian J Med Health. 2024;22(12):51\u20139. https:\/\/doi.org\/10.9734\/ajmah\/2024\/v22i121135.","journal-title":"Asian J Med Health"},{"issue":"1","key":"13946_CR26","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jiph.2020.11.006","volume":"14","author":"M Moussally","year":"2021","unstructured":"Moussally M, Zahreddine N, Kazma J, Ahmadieh R, Kanj SS, Kanafani ZA. Prevalence of antibiotic-resistant organisms among hospitalized patients at a tertiary care center in Lebanon, 2010\u20132018. J Infect Public Health. 2021;14(1):12\u20136. https:\/\/doi.org\/10.1016\/j.jiph.2020.11.006.","journal-title":"J Infect Public Health"},{"issue":"12","key":"13946_CR27","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1016\/j.jiph.2019.02.019","volume":"13","author":"A Chamieh","year":"2020","unstructured":"Chamieh A, El-Hajj G, Zmerli O, Afif C, Azar E. Carbapenem resistant organisms: A 9-year surveillance and trends at Saint George University Medical Center. J Infect Public Health. 2020;13(12):2101\u20136. https:\/\/doi.org\/10.1016\/j.jiph.2019.02.019.","journal-title":"J Infect Public Health"},{"issue":"1","key":"13946_CR28","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13756-019-0487-5","volume":"8","author":"R Moghnieh","year":"2019","unstructured":"Moghnieh R, Araj GF, Awad L, Daoud Z, Mokhbat JE, Jisr T, et al. A compilation of antimicrobial susceptibility data from a network of 13 Lebanese hospitals reflecting the national situation during 2015\u20132016. Antimicrob Resist Infect Control. 2019;8(1):41. https:\/\/doi.org\/10.1186\/s13756-019-0487-5.","journal-title":"Antimicrob Resist Infect Control"},{"key":"13946_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jgar.2021.08.005","volume":"27","author":"RA Moghnieh","year":"2021","unstructured":"Moghnieh RA, Moussa JA, Aziz MA, Matar GM. Phenotypic and Genotypic characterization of cephalosporin-, carbapenem-, and colistin-resistant Gram-negative bacterial pathogens in Lebanon, Jordan, and Iraq. J Glob Antimicrob Resist. 2021;27:1\u20138. https:\/\/doi.org\/10.1016\/j.jgar.2021.08.005.","journal-title":"J Glob Antimicrob Resist"},{"issue":"2","key":"13946_CR30","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.cmi.2020.10.016","volume":"27","author":"ZR Palacios-Baena","year":"2021","unstructured":"Palacios-Baena ZR, Giannella M, Manissero D, Rodr\u00edguez-Ba\u00f1o J, Viale P, Lopes S, et al. Risk factors for carbapenem-resistant Gram-negative bacterial infections: a systematic review. Clin Microbiol Infect. 2021;27(2):228\u201335. https:\/\/doi.org\/10.1016\/j.cmi.2020.10.016.","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"13946_CR31","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s12941-024-00740-0","volume":"23","author":"J Nasr","year":"2024","unstructured":"Nasr J, Abdessamad H, Mina J, Haykal T, Jamil Y, Abboud E, et al. The epidemiology of Gram-negative bacteremia in Lebanon: a study in four hospitals. Ann Clin Microbiol Antimicrob. 2024;23(1):90. https:\/\/doi.org\/10.1186\/s12941-024-00740-0.","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"1","key":"13946_CR32","doi-asserted-by":"publisher","first-page":"14757","DOI":"10.1038\/s41598-021-94295-1","volume":"11","author":"R Moghnieh","year":"2021","unstructured":"Moghnieh R, Abdallah D, Jadayel M, Zorkot W, El Masri H, Dib MJ, et al. Epidemiology, risk factors, and prediction score of carbapenem resistance among inpatients colonized or infected with third-generation cephalosporin-resistant Enterobacterales. Sci Rep. 2021;11(1):14757. https:\/\/doi.org\/10.1038\/s41598-021-94295-1.","journal-title":"Sci Rep"},{"issue":"Suppl 1","key":"13946_CR33","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.1093\/ofid\/ofx162.105","volume":"4","author":"ME Sexton","year":"2017","unstructured":"Sexton ME, Bower C, Sukumaran S, Jacob JT. Comparison of 30- and 90-day mortality rates in patients with cultures positive for carbapenem-resistant Enterobacteriaceae and Acinetobacter in Atlanta, 2011\u20132015. Open Forum Infect Dis. 2017;4(Suppl 1):S44. https:\/\/doi.org\/10.1093\/ofid\/ofx162.105.","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"13946_CR34","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1186\/s12879-022-07436-w","volume":"22","author":"A Vivo","year":"2022","unstructured":"Vivo A, Fitzpatrick MA, Suda KJ, Jones MM, Perencevich EN, Rubin MA, et al. Epidemiology and outcomes associated with carbapenem-resistant Acinetobacter baumannii and carbapenem-resistant Pseudomonas aeruginosa: a retrospective cohort study. BMC Infect Dis. 2022;22(1):491. https:\/\/doi.org\/10.1186\/s12879-022-07436-w.","journal-title":"BMC Infect Dis"},{"issue":"4","key":"13946_CR35","doi-asserted-by":"publisher","first-page":"dlad096","DOI":"10.1093\/jacamr\/dlad096","volume":"5","author":"F Cogliati Dezza","year":"2023","unstructured":"Cogliati Dezza F, Covino S, Petrucci F, Sacco F, Viscido A, Gavaruzzi F, et al. Risk factors for carbapenem-resistant Acinetobacter baumannii bloodstream infections and related mortality in critically ill patients with CRAB colonization. JAC Antimicrob Resist. 2023;5(4):dlad096. https:\/\/doi.org\/10.1093\/jacamr\/dlad096.","journal-title":"JAC Antimicrob Resist"},{"issue":"6","key":"13946_CR36","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.cmi.2025.02.018","volume":"31","author":"S Karakonstantis","year":"2025","unstructured":"Karakonstantis S, Kritsotakis EI, Tziolos RN, Vassilopoulou L, Loukaki M, Kypraiou D, et al. Mortality due to carbapenem-resistant Acinetobacter baumannii bacteraemia: a 5-year cohort study in intensive care patients. Clin Microbiol Infect. 2025;31(6):1033\u20139. https:\/\/doi.org\/10.1016\/j.cmi.2025.02.018.","journal-title":"Clin Microbiol Infect"},{"issue":"9","key":"13946_CR37","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1016\/j.ajic.2019.03.003","volume":"47","author":"X Du","year":"2019","unstructured":"Du X, Xu X, Yao J, Deng K, Chen S, Shen Z, et al. Predictors of mortality in patients infected with carbapenem-resistant Acinetobacter baumannii: A systematic review and meta-analysis. Am J Infect Control. 2019;47(9):1140\u20135. https:\/\/doi.org\/10.1016\/j.ajic.2019.03.003.","journal-title":"Am J Infect Control"},{"issue":"1","key":"13946_CR38","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13756-017-0297-6","volume":"7","author":"ZA Kanafani","year":"2018","unstructured":"Kanafani ZA, Zahreddine N, Tayyar R, Sfeir J, Araj GF, Matar GM, et al. Multi-drug resistant Acinetobacter species: a seven-year experience from a tertiary care center in Lebanon. Antimicrob Resist Infect Control. 2018;7(1):9. https:\/\/doi.org\/10.1186\/s13756-017-0297-6.","journal-title":"Antimicrob Resist Infect Control"},{"issue":"4","key":"13946_CR39","doi-asserted-by":"publisher","first-page":"e0282276","DOI":"10.1371\/journal.pone.0282276","volume":"18","author":"JA Frem","year":"2023","unstructured":"Frem JA, Doumat G, Kazma J, Gharamti A, Kanj SS, Fayad AGA, et al. Clinical predictors of mortality in patients with Pseudomonas aeruginosa infection. PLoS ONE. 2023;18(4):e0282276. https:\/\/doi.org\/10.1371\/journal.pone.0282276.","journal-title":"PLoS ONE"},{"key":"13946_CR40","doi-asserted-by":"publisher","first-page":"1407246","DOI":"10.3389\/fcimb.2024.1407246","volume":"14","author":"G Sobh","year":"2024","unstructured":"Sobh G, Araj GF, Finianos M, Sourenian T, Hrabak J, Papagiannitsis CC, et al. Molecular characterization of carbapenem and ceftazidime-avibactam-resistant Enterobacterales and horizontal spread of blaNDM-5 gene at a Lebanese medical center. Front Cell Infect Microbiol. 2024;14:1407246. https:\/\/doi.org\/10.3389\/fcimb.2024.1407246.","journal-title":"Front Cell Infect Microbiol"},{"key":"13946_CR41","doi-asserted-by":"publisher","first-page":"8831804","DOI":"10.1155\/2023\/8831804","volume":"2023","author":"M Fadlallah","year":"2023","unstructured":"Fadlallah M, Salman A, Salem-Sokhn E. Updates on the status of carbapenem-resistant Enterobacterales in Lebanon. Int J Microbiol. 2023;2023:8831804. https:\/\/doi.org\/10.1155\/2023\/8831804.","journal-title":"Int J Microbiol"},{"issue":"9","key":"13946_CR42","doi-asserted-by":"publisher","first-page":"e0203323","DOI":"10.1371\/journal.pone.0203323","volume":"13","author":"C Dagher","year":"2018","unstructured":"Dagher C, Salloum T, Alousi S, Arabaghian H, Araj GF, Tokajian S. Molecular characterization of Carbapenem resistant Escherichia coli recovered from a tertiary hospital in Lebanon. PLoS ONE. 2018;13(9):e0203323. https:\/\/doi.org\/10.1371\/journal.pone.0203323.","journal-title":"PLoS ONE"},{"issue":"3","key":"13946_CR43","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/S1473-3099(21)00399-6","volume":"22","author":"M Wang","year":"2022","unstructured":"Wang M, Earley M, Chen L, Hanson BM, Yu Y, Liu Z, et al. Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): a prospective cohort study. Lancet Infect Dis. 2022;22(3):401\u201312. https:\/\/doi.org\/10.1016\/S1473-3099(21)00399-6.","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"13946_CR44","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.jiph.2012.02.003","volume":"5","author":"RI El-Herte","year":"2012","unstructured":"El-Herte RI, Kanj SS, Matar GM, Araj GF. The threat of carbapenem-resistant Enterobacteriaceae in Lebanon: an update on the regional and local epidemiology. J Infect Public Health. 2012;5(3):233\u201343. https:\/\/doi.org\/10.1016\/j.jiph.2012.02.003.","journal-title":"J Infect Public Health"},{"key":"13946_CR45","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ijid.2014.07.017","volume":"29","author":"D Hammoudi","year":"2014","unstructured":"Hammoudi D, Ayoub Moubareck C, Aires J, Adaime A, Barakat A, Fayad N, et al. Countrywide spread of OXA-48 carbapenemase in Lebanon: surveillance and genetic characterization of carbapenem-non-susceptible Enterobacteriaceae in 10 hospitals over a one-year period. Int J Infect Dis. 2014;29:139\u201344. https:\/\/doi.org\/10.1016\/j.ijid.2014.07.017.","journal-title":"Int J Infect Dis"},{"issue":"021","key":"13946_CR46","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.3855\/jidc.10100","volume":"12","author":"SS Kanj","year":"2018","unstructured":"Kanj SS, Tayyar R, Shehab M, El-Hafi B, Rasheed SS, Kissoyan KA, et al. Increase of blaOXA-23-like in Acinetobacter baumannii at a tertiary care center in Lebanon between 2007 and 2013. J Infect Dev Ctries. 2018;12(021):S4\u20134. https:\/\/doi.org\/10.3855\/jidc.10100.","journal-title":"J Infect Dev Ctries"},{"key":"13946_CR47","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ijid.2016.09.017","volume":"52","author":"A Al Atrouni","year":"2016","unstructured":"Al Atrouni A, Hamze M, Jisr T, Lemari\u00e9 C, Eveillard M, Joly-Guillou ML, et al. Wide spread of OXA-23-producing carbapenem-resistant Acinetobacter baumannii belonging to clonal complex II in different hospitals in Lebanon. Int J Infect Dis. 2016;52:29\u201336. https:\/\/doi.org\/10.1016\/j.ijid.2016.09.017.","journal-title":"Int J Infect Dis"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-13946-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13946-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13946-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:41:29Z","timestamp":1790847689000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-13946-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["13946"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-13946-8","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"assertion":[{"value":"26 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study has been approved by the institutional review board at the American University of Beirut under identification number BIO-2017-0479 with a waiver of consent. This research is adherent to all principles stated by the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The authors of this manuscript have conflicts of interest to disclose as described BioMed Central Infectious Diseases. All authors report funding support from the ARLG of the National Institutes of Health (NIH) and the National Institute of Allergy and Infectious Diseases (NIAID; UM1AI104681) during the conduct of this study. JFJ, HK, EJ, JRH, SFH, ZAK, NKZ, AGA, LK, YL, JJ, GFA, and GMM have nothing to declare other than ARLG grant paid to their institution. YD reports grants paid to his institutions by Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science, honorarium paid to him by Shionogi, and serving on advisory boards for GSK, Shionogi, and Meiji Seika Pharma. VGF reports grants to his institution from Merck, Contrafect, Karius, Basilea, Janssen, AstraZeneca, EDE (Exponential Deep Examination); royalties from UpToDate; personal fees from Akagera, AstraZeneca, Armata, Basilea, Debiopharm, GSK, Integrated Biotherapeutics, Karius; pending patent for a host gene expression signature diagnostic for sepsis; and stock options with Valanbio. DLP serves on the Scientific Advisory Board of the Antibiotic Action Fund, has grant funding from Shionogi, Pfizer and Merck and serves on advisory boards or has given lectures for Pfizer, Merck, bioMerieux, Zuellig, Entasis, QPex and VenatoRx. MJS reports grants\/contracts to his institution from Melinta, Merck, Selux Diagnostics, SNIPRBiome, and bioM\u00e9rieux; and compensation for participation on a DSMB from AbbVie paid directly to him. DVD reports grants and contracts from the NIH, Merck, and Shinogi; consultancy for Actavis, Tetraphase, Sanofi-Pasteur, MedImmune, Astellas, Merck, Allergan, T2Biosystems, Roche, Achaogen, Neumedicine, Shionogi, Pfizer, Entasis, Qpex, Wellspring, Karius, Teva, and Utility paid directly to him; honoraria from Pfizer; and an editor\u2019s stipend from the British Society for Antimicrobial Chemotherapy (BSAC). SKS received speaker honoraria from MSD, Pfizer, Gilead, Menarini, and Hikma.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"1746"}}